openPR Logo
Press release

Creative Peptides Released GMP Synthesis Service

09-04-2018 10:06 AM CET | Health & Medicine

Press release from: Creative Peptides

Located in Shirley, New York, the world’s leading peptide supplier Creative Peptides announced the launch of its GMP synthesis (https://www.creative-peptides.com/services/custom-gmp-peptide-synthesis-services.html ) business on August 29, 2018. Now this company is focused on the development and GMP manufacturing of pharmaceutical grade peptides.
As the demand of pharmaceutical market continues to grow, more and more pharmas and research institutions choose the CMO and CRO models to expand their businesses, which is more cost-saving, efficient without additional expenses on staff, equipment and other infrastructure. Creative Peptides has become the first choice to outsource the manufacturing of peptides or active pharmaceutical ingredients (APIs) in any quantities, owing to its world-in-class technologies, strong technical staff and strict quality control systems.
“We are able to produce GMP peptides, APIs in annual quantities as needed by our customers. The availability of low-cost active pharmaceutical ingredients from our company has had a big impact in the international community,” said Dr. Robert Martinez, Head of Creative Peptides’ synthesis businesses, in a statement. “Our robust, economical manufacturing processes will definitely help optimize the costs of drug discovery and development. A full range of synthetic technologies are available. But as to which technology to be used, the final choice depends on the sequence length, the scale, and the specific project requirements.”
The GMP synthesis range at Creative Peptides includes:
Large-Scale Liquid (Solution) Phase Peptide Synthesis (LPPS)
Large-Scale Solid Phase Peptide Synthesis (SPPS)
Large-Scale Hybrid Fragment Synthesis Peptide
Modifications
Large-Scale Purification
Large-Scale Isolation
Whenever and wherever, quality control is the top priority for Creative Peptides. The GMP production sites were designed in strict accordance to US-FDA guidelines. All have passed US-FDA inspections. Currently this company is qualified for the manufacturing of generic APIs in compliance with ICH guidelines including Q7 and other related and applicable sections.
>98% purity of the GMP synthetic products is guaranteed. Standard QC tests before releasing GMP products are also provided. Extra tests can be made as well according to the requests of clients.

About Creative Peptides
With a high profile team of experts in multiple fields such as peptide technology and synthetic chemistry, Creative Peptides not only provides various research peptides, like anti-pigmentation peptide (https://www.creative-peptides.com/product/anti-pigmentation-54.html), neoantigen (https://www.creative-peptides.com/services/neoantigen-peptides-vaccine-synthesis-service.html), glucagon like peptides, but also dedicates to solving the problems that trouble its clients by offering various GMP synthesis services.

Creative Peptides

45-16 Ramsey Road, Shirley, NY 11967, USA

Caroline Miller

contact@creative-peptides.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Peptides Released GMP Synthesis Service here

News-ID: 1217565 • Views:

More Releases from Creative Peptides

Creative Peptides Released One-Stop Solution for All Peptide Drug Conjugate Need …
New York, United States-Sep 5, 2022-Peptide drug conjugate (PDC) is emerging as a novel type of conjugate drug, showing advantageous features over antibody-drug conjugates (ADCs). As a dedicated peptide manufacturer, Creative Peptides provides a one-stop solution for all peptide drug bioconjugation needs to help pharmaceutical clients bring more PDCs to the market. Structurally, PDC mainly contains three elements-cytotoxin, linker, and targeted peptide, in which a specific peptide sequence covalently connects with
Creative Peptides Rolls Out PNA FISH Probes with High Sensitivity and Specific H …
New York, United States - March 22, 2022-Creative Peptides, as a pioneering biomedical technology company in the United States, is qualified to provide highly specific products and services for life science research. To promote PNA biology research, Creative Peptides offers various PNA FISH probes such as telomere probes and CAG repeat probes. Fluorescence in situ hybridization (FISH) is a cytogenetic method to detect and target the presence or absence of specific

More Releases for Peptide

Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be? In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights: • Global Peptide Cancer Drug Market Insight By Region & Indication • Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion • Approved Peptide Cancer Drugs: > 30 Drugs • Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis • Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase • Insight On Peptide Cancer Drugs In Clinical Trials: >
Growing Adoption of Synthetic Peptide Drugs Driving Peptide Therapeutics Market …
Peptide Therapeutics Market size was valued at USD 40.69 billion in 2019 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031). [https://www.skyquestt.com/report/peptide-therapeutics-market] size was valued at USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031). The increasing prevalence of
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established